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OBJECTIVES This study sought to determine the long-term safety and efficacy of co-administered
fenofibrate (FENO) and ezetimibe (EZE) in patients with mixed hyperlipidemia.
BACKGROUND Both EZE and FENO offer complementary benefits to the lipid profile of patients with
mixed hyperlipidemia.
METHODS After completing the 12-week randomized, double-blind base study that compared EZE 10 mg,
FENO160mg, FENO160mg plus EZE10mg, and placebo in patients withmixed hyperlipidemia,
patients continued into a double-blind, 48-week extension phase. Those patients in the FENO plus
EZE and FENO groups continued on their respective base study treatment, and patients in the
EZE and placebo groups were switched to FENO plus EZE and FENO, respectively.
RESULTS Of the 587 patients who completed the base study, 576 continued into the extension study (n 
340 in FENO plus EZE and n 236 in FENO). The FENO plus EZE produced significantly
greater reductions in low-density lipoprotein-cholesterol compared with FENO (22% vs.9%,
respectively; p  0.001). There were also significantly greater improvements in triglycerides,
high-density lipoprotein cholesterol (HDL-C), total cholesterol, non–HDL-C, and apolipopro-
tein B with FENO plus EZE compared with FENO. Changes in apolipoprotein A-I and
high-sensitivity C-reactive protein were similar between groups. Overall, FENO plus EZE was
well tolerated during the extension study. The proportion of patients with consecutive elevations
of alanine aminotransferase/aspartate aminotransferase 3 times upper limit of normal were
similar between the FENO plus EZE (1.2%) and FENO (1.7%) groups. No cases of creatine
phosphokinase elevations10 times upper limit of normal ormyopathy were observed in either group.
CONCLUSIONS Long-term, 48-week co-administration of FENO plus EZE was well tolerated and more
efficacious than FENO in patients with mixed hyperlipidemia. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.0721584–7) © 2006 by the American College of Cardiology Foundation
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she cholesterol absorption inhibitor ezetimibe (EZE) effec-
ively lowers low-density lipoprotein cholesterol (LDL-C) by
nhibiting the intestinal absorption of dietary and biliary
holesterol without affecting absorption of triglycerides or
at-soluble vitamins (1). Fibrates have favorable effects on
riglycerides, high-density lipoprotein cholesterol (HDL-C),
nd LDL particle size (2). Recently in patients with mixed
yperlipidemia, 12-week co-administration of fenofibrate
FENO) plus EZE was well tolerated and produced signif-
cant improvements in lipid profiles compared with either
ENO or EZE alone (3). Thus, in the short term, the
o-administration of FENO plus EZE, through their com-
From *National Clinical Research Inc., Richmond, Virginia; †Point Medical,
ijon, France; ‡Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong;
Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky;
nd ¶Merck Research Laboratories, Rahway, New Jersey. This study was funded by
erck/Schering-Plough Pharmaceuticals, North Wales, Pennsylvania. Dr. McK-
nney has received speaking honorarium for AstraZeneca, KOS, Merck, and
fizer and grant support from AstraZeneca, GSK, KOS, Merck, Pfizer, and
akeda, and has provided consulting services to AstraZeneca, KOS, Merck,
fizer, and Sankyo. Dr. Bays, in over a decade of clinical research, has served as
clinical investigator for (and has received research grants from) pharmaceutical
ompanies such as Abbott, Alteon, Arena, AstraZeneca, Aventis, Bayer, Boehr-
nger Ingelheim, Boehringer Mannheim, Bristol Myers Squibb, Esperion, Fuji-
awa, Ciba Geigy, GelTex, Glaxo, Genetech, Hoechst Roussel, KOS, Kowa, 2lementary mechanisms of action, provides another thera-
eutic option for treating patients with mixed hyperlipid-
mia. The present study examined the long-term safety and
fficacy of co-administered FENO plus EZE in patients
ith mixed hyperlipidemia over 48 weeks.
ETHODS
tudy design. Study design and results for the 12-week base
tudy were published previously (3). For the base study, mixed
yperlipidemia was defined as a baseline LDL-C level of 130
o 220 mg/dl inclusive (100 to 180 mg/dl for patients with type
ederle, Marion Merrell Dow, Merck, Merck Schering Plough, Miles, Novartis,
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s a consultant, speaker, and/or advisor to and for pharmaceutical companies such
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arlson, Davies, Mitchel, and Gumbiner are employees of Merck and may hold
tocks or stock options in Merck.
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April 18, 2006:1584–7 Long-Term Co-Administered Fenofibrate and Ezetimibediabetes) and a baseline triglyceride level of 200 to 500 mg/dl
nclusive. After completing the 12-week base study, which
ompared EZE 10 mg, FENO 160 mg, FENO 160 mg plus
ZE 10 mg, and placebo, patients continued into the 48-week
ouble-blind extension study unless there was a condition that
ould interfere with the patient’s ability to participate. Patients
n the FENO plus EZE and FENO groups continued on their
espective base study treatment, and those in the EZE and
lacebo groups were switched to FENO plus EZE and
ENO, respectively. All patients were instructed to continue
ollowing the National Cholesterol Education Program
NCEP) Step I or comparable diet throughout the study.
ollow-up visits were conducted at weeks 6, 12, 24, 36, and 48
f the extension study.
afety assessment. Safety and tolerability were evaluated by
dverse experiences (AEs), laboratory measurements (specifi-
ally alanine aminotransferase [ALT], aspartate aminotrans-
erase [AST], and creatine phosphokinase [CPK] levels), and
hysical examination findings for only the 48-week extension
tudy. Results were not combined with the 12-week base study.
he study investigators assessed the potential relationship of all
Es to drug treatment while blinded to treatment assignment
Appendix). The AEs of clinical interest that resulted in
iscontinuation included: consecutive, unexplained elevations
f CPK 10 times the upper limit of normal (ULN) or
LT/AST 3 times ULN; myopathy (muscle symptoms
ccompanied by CPK 10 times ULN); persistent elevations
n serum creatinine 1.8 mg/dl or 30% above the baseline
alue from base study for patients with baseline creatinine
evels 1.0 mg/dl; persistent elevations in creatinine 50%
bove the baseline value of base study for patients with baseline
reatinine levels 1.0 mg/dl. Beginning at week 12 of the
xtension, if the LDL-C concentration was 15 mg/dl above
he patient’s NCEP Adult Treatment Panel III risk-specific
DL-C target as established at baseline, the patient was
iscontinued for lack of efficacy.
fficacy assessments. The primary efficacy variable was
ercent change in LDL-C from baseline of the base study to
tudy end point in the extension. Secondary efficacy end
oints included percent change from baseline to study end
oint in total cholesterol (TC), HDL-C, triglycerides,
on–HDL-C, apolipoprotein B, apolipoprotein A-I, and
Abbreviations and Acronyms
AE  adverse experience
ALT  alanine aminotransferase
AST  aspartate aminotransferase
CPK  creatine phosphokinase
EZE  ezetimibe
FENO  fenofibrate
HDL-C  high-density lipoprotein-cholesterol
hs-CRP  high-sensitivity C-reactive protein
LDL-C  low-density lipoprotein-cholesterol
TC  total cholesterol
ULN  upper limit of normaligh-sensitivity C-reactive protein (hs-CRP).
h
caboratory measurements. A central laboratory per-
ormed all clinical laboratory analyses of safety and efficacy
ariables as described previously (3).
tatistical analyses. Inferential testing was limited to a
re-specified number of safety parameters, including myop-
thy, persistent ALT and/or AST elevations 3 times
LN, persistent CPK elevations 10 times ULN, planned
r performed cholecystectomy (pooled end point including
erformed cholecystectomy or diagnosed cholecystitis,
holangitis, or cholelithiasis), and serum creatinine 1.5
g/dl. Proportions of patients were compared between
reatments with the Fisher exact test. Given the differences
n average duration of exposure to active therapy between
roups in the present study, examining the crude incidence
ates may be misleading. Therefore, adjusted incidence rates
er 1,000 patient-years were calculated for the pre-specified
afety parameters listed above based on cumulative patient-
ears available for each treatment (i.e., adjusted incidence
ate  number of events/exposure [expressed in 1,000
atient-years]). The efficacy analysis was an all-patients-
reated approach with an end point defined as percent
hange from baseline to the average of all measurements
vailable throughout extension. A parametric analysis of
ovariance (ANCOVA) model with terms for treatment
nd baseline triglyceride values was used to compare each
fficacy variable between treatment groups. Because triglyc-
rides and hs-CRP were not normally distributed, a non-
arametric ANCOVA was used to assess between-group
ifferences. Least-squares mean or median differences be-
ween treatment groups with corresponding 95% CIs were
ummarized.
able 1. Baseline* Summary of Patient Demographics, Lipid
arameters, and hs-CRP
Study Variable
FENO
(n  236)
FENO  EZE
(n  340)
ge, yrs 52.9 (10.4) 54.1 (9.5)
atients 65 yrs, n (%) 34 (14.4) 53 (15.6)
ender, n (%)
Male 139 (58.9) 192 (56.5)
Female 97 (41.1) 148 (43.5)
ody mass index 29.3 (4.4) 29.5 (4.6)
ype 2 diabetes, n (%) 33 (14.0) 60 (17.6)
etabolic syndrome, n (%) 138 (59.0) 190 (55.9)
DL-C, mg/dl 164.1 (27.9) 159.7 (27.7)
DL-C, mg/dl 41.9 (9.5) 41.7 (8.8)
riglycerides,† mg/dl 277.0 (86.5) 275.0 (101.6)
C, mg/dl 264.4 (33.5) 259.9 (32.2)
on–HDL-C, mg/dl 222.6 (31.8) 218.2 (31.0)
po B, mg/dl 171.3 (25.0) 167.8 (24.5)
po A-I, mg/dl 151.0 (28.5) 149.1 (25.7)
s-CRP,† mg/l 3.0 (4.0) 2.5 (3.1)
Baseline values as recorded in the base study (reference 3). Data are expressed as
ean (standard deviation [SD]) or frequency unless otherwise indicated. †Values are
edian (robust SD for median).
Apo  apolipoprotein; hs-CRP  high-sensitivity C-reactive protein; EZE 
zetimibe; FENO  fenofibrate; HDL-C  high-density lipoprotein-cholesterol;
s-CRP  high-sensitivity C-reactive protein; LDL-C  low-density lipoprotein-
holesterol; TC  total cholesterol.
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f the 587 patients who completed the 12-week base study,
76 patients continued into the 48-week extension study
N  340 for FENO plus EZE and N  236 for FENO;
able 1). During the extension phase, a greater proportion
f participants in the FENO group discontinued treatment
ompared with those in the FENO plus EZE group, primarily
ecause of the failure to meet the LDL-C efficacy criterion
Table 2). Thus, average exposure to study treatment was
ess in the FENO group (212.3 days) compared with the
ENO plus EZE group (271.3 days).
The FENO plus EZE resulted in significantly greater
ercent reductions from baseline to average extension end
oint in LDL-C, TC, triglycerides, non–HDL-C, and apoli-
oprotein B compared with FENO (Table 3). The percent
ncrease in HDL-C, but not apolipoprotein A-I, was signifi-
antly greater with FENO plus EZE versus FENO. Reduc-
ions in median hs-CRP levels were not different between
reatments.
The FENO plus EZE was well tolerated during the
8-week extension study. Both groups were similar with
egard to incidence of treatment-related AEs and discon-
inuations because of treatment-related AEs, respectively
Table 4). Five patients had treatment-related serious AEs
able 2. Disposition of Patients Entered Into the 48-Week
xtension Study
FENO
(n  236)
FENO  EZE
(n  340)
atient completed 87 (36.9) 230 (67.6)
atient discontinued 149 (63.1) 110 (32.4)
Due to lack of efficacy* 120 (50.8) 82 (24.1)
Due to clinical adverse experience 7 (3.0) 5 (1.5)
Due to laboratory adverse experience 7 (3.0) 10 (2.9)
Due to other reasons† 15 (6.4) 13 (3.8)
ata are expressed as n (%). *Lack of efficacy was defined as LDL-C 15 mg/dl
bove NCEP ATP III risk-specific LDL-C goal at week 12 or later during the
xtension. †Other reasons include patients who withdrew consent, moved, deviated
rom protocol, or were lost to follow-up.
NCEP ATP III  U.S. National Cholesterol Education Program Adult Treat-
ent Panel III; other abbreviations as in Table 1.
Table 3. Comparison of the Lipid and hs-CRP
Regard to Percent Change From Baseline Valu
the Extension Study
Parameter
FENO
(n  235)
LDL-C 8.6 (10.6 to 6.5)
HDL-C 17.8 (15.9 to 19.8)
Triglycerides† 41.8 (44.9 to 38.7)
TC 13.6 (15.0 to 12.1)
Non–HDL-C 19.4 (21.2 to 17.6)
Apo B 16.2 (18.5 to 13.9)
Apo A-I 7.8 (5.5 to 10.1)
hs-CRP† 21.1 (29.0 to 13.1)
*Baseline values were recorded at the beginning of the base st
change (95% CI). †Median percent change (95% CI); for a
FENO  EZE; for hs-CRP, n  221 for FENO and n  326 f
Abbreviations as in Table 1.n the extension study: three in the FENO group (angio-
eurotic edema, pancreatitis, polyarthropathy) and two in
he FENO plus EZE group (cholangitis, cholecystitis). A
atient on FENO plus EZE died in the extension study
rom a cerebral hemorrhage that the investigator reported
as definitely not caused by study treatment.
No patient experienced CPK elevations10 times ULN or
yopathy. The proportion of patients with consecutive eleva-
ions of ALT and/or AST3 times ULNwas low and similar
etween treatment groups (Table 4). The proportion of pa-
ients with planned or performed cholecystectomy was not
ignificantly different between treatments (Table 4). To ac-
ount for differences in exposure to treatments, rates of planned
r performed cholecystectomy were adjusted for exposure
expressed in 1,000 patient-years) and were still not signifi-
ects of FENO and FENO Plus EZE With
the Base Study* to the End Point Values in
Extension Study
FENO  EZE
(n  337) p Value
22.0 (23.7 to 20.3) 0.001
20.9 (19.2 to 22.5) 0.02
46.0 (48.2 to 43.8) 0.002
23.2 (24.4 to 22.0) 0.001
31.6 (33.1 to 30.1) 0.001
25.2 (27.1 to 23.3) 0.001
10.1 (8.2 to 12.0) 0.12
25.3 (33.1 to 17.5) 0.46
eference 3); data are expressed as least-squares mean percent
proteins B and A-I, n  217 for FENO and n  321 for
able 4. Safety and Tolerability Summary for 48-Week
xtension Study
Number (%) of Patients With
FENO
(n  236)
FENO  EZE
(n  340)
ne or more AEs 145 (61.4) 229 (67.4)
Treatment-related AEs 38 (16.1) 47 (13.8)
SAEs 14 (5.9) 23 (6.8)
Treatment-related SAEs 3 (1.3) 2 (0.6)
Deaths 0 (0.0) 1 (0.3)
iscontinuations due to AEs 14 (5.9) 15 (4.4)
Discontinuations due to
treatment-related AEs
13 (5.5) 13 (3.8)
Discontinuations due to SAEs 2 (0.9) 3 (0.8)
Discontinuations due to
treatment-related SAEs
2 (0.9) 2 (0.6)
Es of interest
ALT and/or AST 3 times
ULN consecutive
4/235 (1.7) 4/337 (1.2)
CPK 10 times ULN 0/235 0/337
Myopathy 0 0
Planned or performed
cholecystectomy
1 (0.4) 4 (1.2)
Serum creatinine 1.5 mg/dl 21/235 (8.9) 36/338 (10.7)
Es  adverse experiences; ALT  alanine aminotransferase; AST  aspartate
minotransferase; CPK  creatine phosphokinase; SAEs  serious adverse experi-
nces; ULN  upper limit of normal; other abbreviations as in Table 1.Eff
es in
udy (r
polipoor FENO  EZE.
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15.9 per 1,000 patient-years [95% CI 4.3 to 40.7] vs. 7.3 per
,000 patient-years [95% CI 0.2 to 40.6], respectively). The
roportion of patients with serum creatinine 1.5 mg/dl was
ot significantly different between groups (Table 4). The
esults of all other measures of safety did not suggest any
linically meaningful differences between treatment groups.
ISCUSSION
o-administration of FENO plus EZE provided superior
ipid-altering effects compared with FENO during the
8-week extension study. In the present study, FENO plus
ZE produced an incremental LDL-C reduction of 13.5%
ompared with FENO. This was consistent with the incre-
ental reduction observed for FENO plus EZE versus FENO
n the base study (3) and also that observed with EZE plus
tatin versus statin monotherapy (4). Improvements in TC,
on–HDL-C, TG, HDL-C, and apolipoprotein B were also
reater in the co-administration group. The results from the
xtension study were generally consistent with those from
he base study, and the small differences in efficacy between
tudies (TG and HDL-C) may be because the extension
tudy was not randomly assigned and was imbalanced.
The safety profile for long-term co-administration of
ENO plus EZE was similar to that of FENO in this study.
roups did dramatically differ in the overall rate of discontinu-
tions, which was mainly attributable to an imbalance in the
umber of patients who discontinued because of the protocol-
pecified lack of LDL-C efficacy criterion used in the exten-
ion, which was more than double in the FENO group versus
he FENO plus EZE group. This imbalance was related to the
reater lipid efficacy of FENO plus EZE compared with
ENO. As a result of this difference, patients in the FENO
lus EZE group averaged approximately 8.5 more weeks of
reatment exposure than those in the FENO group.
No clinically important elevations in CPK or cases of
yopathy were observed in either treatment group during
he extension. The incidence of elevated ALT and/or AST
evels3 times ULN was low and was not different between
reatment groups. Fenofibrate increases cholesterol excre-
ion into the bile, which may lead to cholelithiasis (5).
zetimibe has inconsistent effects on biliary cholesterol in
nimal models (6). There seems, however, to be no evi-
ence, based on short-term clinical study data available to
ate, that EZE monotherapy increases the risk of gallstones
n patients with primary hypercholesterolemia (1,7,8). In
his study, most randomized patients had numerous risk
actors, including hyperlipidemia, obesity, age, female gen-
er, and type 2 diabetes, that would predispose them to an
ncreased risk for gallstones (9). Patients were excluded from
he present study for a history of gallbladder disease and not
reviously having been treated with cholecystectomy. The
roportion of patients with performed or planned cholecys-
ectomy was not significantly different between groups when oxpressed as either the proportion of patients with events or
he incidence rates adjusted for group differences in patient
xposure to treatments. This study was, however, not
esigned to assess infrequently occurring AEs such as
holecystectomy, and only a much larger, longer-term study
ould conclusively assess these infrequent biliary AEs.
Although modest increases in the incidence of serum
reatinine level 1.5 mg/dl were found in both treatment
roups, the proportion of patients with these elevated
reatinine levels did not differ between groups. The increase
n both groups might have been anticipated, because FENO
s known to increase creatinine levels (5). The overall safety
rofile of co-administered FENO plus EZE in this longer-
erm 48-week study was consistent with the findings in the
horter 12-week base study (3). Furthermore, considering
he greater mean duration of treatment exposure for patients
n the FENO plus EZE group compared with those in the
ENO group in this study, the comparable safety findings
etween treatment groups support co-administration of
ENO plus EZE as a well-tolerated therapy.
In summary, the long-term FENO plus EZE therapy
as a more effective treatment option than FENO, and was
ell-tolerated for up to 48 weeks of treatment for patients
ith mixed hyperlipidemia in this study.
eprint requests and correspondence: Dr. James M. McKenney,
ational Clinical Research Inc., 2809 Emerywood Parkway, Suite
40, Richmond, Virginia 23294. E-mail: jmckenney@ncrinc.net.
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